Trial reportBritish journal of cancer2003
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.
Trial report in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 105 citations in OpenAlex.
- Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.British journal of cancer · 2008Trial
- Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.British journal of cancer · 2003Trial
- First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors.Cell reports. Medicine · 2025Article
- Delivery of STING agonists for cancer immunotherapy.Current opinion in biotechnology · 2024Review
- Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas.Seminars in radiation oncology · 2024Review
- Targeted disruption of tumor vasculature via polyphenol nanoparticles to improve brain cancer treatment.Cell reports. Physical science · 2022Article
- The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.Frontiers in immunology · 2022Article
- Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature.Oncotarget · 2022Article
- Trial watch: STING agonists in cancer therapy.Oncoimmunology · 2020Review
- Chemophototherapy: An Emerging Treatment Option for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017Review
- A cooperative polymeric platform for tumor-targeted drug delivery.Chemical science · 2016Article
- Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.Molecular pharmaceutics · 2013Article
- Targeted anti-vascular therapies for ovarian cancer: current evidence.British journal of cancer · 2013Review
- Microbubble and ultrasound radioenhancement of bladder cancer.British journal of cancer · 2012Article
- Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.Biochemical pharmacology · 2011Article
- Cardiovascular toxicity profiles of vascular-disrupting agents.The oncologist · 2011Article
- Temporal aspects of the action of ASA404 (vadimezan; DMXAA).Expert opinion on investigational drugs · 2010Review
- Antivascular ultrasound therapy extends survival of mice with implanted melanomas.Ultrasound in medicine & biology · 2010Article
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.The Lancet. Oncology · 2010Review
- A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.British journal of cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this phase I, dose-escalation study was to determine the toxicity, maximum tolerated dose, pharmacokinetics, and pharmacodynamic end points of 5,6-dimethylxanthenone acetic acid (DMXAA). In all, 46 patients received a total of 247 infusions of DMXAA over 15 dose levels ranging from 6 to 4900 mg x m(-2). The maximum tolerated dose was established at 3700 mg x m(-2); dose-limiting toxicities in the form of urinary incontinence, visual disturbance, and anxiety were observed at the highest dose level (4900 mg x m(-2)). The pharmacokinetics of DMXAA were dose dependent. Peak concentrations and area under the curve level increased from 4.8 microM and 3.2 microM h, respectively, at 6 mg x m(-2) to 1290 microM and 7600 microM h at 3700 mg x m(-2), while clearance declined from 7.4 to 1.7 l h(-1) x m(-2) over the same dose range. The terminal half-life was 8.1+/-4.3 h. More than 99% of the drug was protein bound at doses up to 320 mg x m(-2); at higher doses the percent free drug increased to a maximum of 6.9% at 4900 mg x m(-2). Dose-dependent increases in the serotonin metabolite 5-hydroxyindoleacetic acid were observed at dose levels of 650 mg x m(-2) and above. There was one unconfirmed partial response at 1300 mg x m(-2). In conclusion, DMXAA is a novel vascular targeting agent and is well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.